iStent as a Solo Procedure for Glaucoma Patients: A Systematic Review and Meta-Analysis

Abstract

BackgroundGlaucoma is a leading cause of irreversible blindness. It is firmly entrenched in the traditional treatment paradigm to start with pharmacotherapy. However, pharmacotherapy is not benign and has been well documented to have a number of significant challenges. Minimally invasive glaucoma surgery (MIGS) that targets the outflow pathway with minimal to no scleral dissection has resulted in the need to reconsider the glaucoma treatment paradigm.PurposeTo perform a systematic review and meta-analysis to evaluate and quantify the effect on post-operative intraocular pressure (IOP) and number of topical glaucoma medications, in patients receiving the iStent MIGS device as the solo procedure without concurrent cataract surgery.MethodsA systematic review was conducted by searching various databases between January 1, 2000, and June 30, 2014. Studies reporting up to a maximum follow-up period of 24 months were retrieved and screened using the EPPI-Reviewer 4 gateway. Percentage reduction in IOP (IOPR%), and mean reduction in topical glaucoma medications after surgery were computed. Meta-analysis was performed using STATA v. 13.0. The standardized mean difference (SMD) was calculated as the effect size for continuous scale outcomes. Heterogeneity was determined using the I 2 statistics, Z-value, and χ2 statistics. Fixed-effect and random-effect models were developed based on heterogeneity. Sub-group analysis was performed based on the number of iStents implanted and the follow-up period. The outcome measures were changes in the IOP and number of glaucoma medications.ResultsThe search strategy identified 105 records from published literature and 9 records from the grey literature. Five studies with 248 subjects were included for quantitative synthesis. A 22% IOP reduction (IOPR%) from baseline occurred at 18-months after one iStent implant, 30% at 6-months after two iStents implantations, and 40% at 6-months after implantation of three iStents. A mean reduction of 1.2 bottles per patient of topical glaucoma medications occurred at 18-months after one iStent implant, 1.45 bottles per patient at 6-months after two iStents, and one bottle of medication per patient was reduced at 6-months following placement of three iStents implants. Meta-analysis results showed a significant reduction in the IOP after one iStent (SMD = -1.68, 95% CI: [-2.7, -0.61]), two iStents (SMD = -1.88, 95% CI: [-2.2, -1.56]), and three iStents (SMD = -2, 95% CI: [-2.62, -1.38]) implantation. Results showed a significant drop in the topical glaucoma medications after one iStent (SMD = -2.11, CI: [-3.95, -0.27]), two iStent (SMD = -1.88, CI: [-2.20, -1.56]), and three iStents (SMD = -2.00, CI: [-2.62, -1.38]) implantation. The maximum reduction in IOP occurred at 12-months (SMD = -2.21, CI: [-2.53, -1.88]) and a significant reduction in post-operative topical glaucoma medications occurred even after 18-months of iStent implantation (SMD = -0.71, CI: [-1.15, -0.26]).ConclusioniStent implantation as a solo procedure without concurrent cataract extr...

Minimally invasive glaucoma surgery: Comparison of iStent with iStent inject in primary open angle glaucoma

“…The meta‐analysis also demonstrated a significant reduction in the number of glaucoma medications used after the procedure in the combined group compared with the phacoemulsification only group (weighted mean reduction of 1.33 from baseline compared with 1.01) . Significant reduction in IOP from baseline has also been demonstrated in patients with mild to moderate glaucoma treated with stent insertion alone at follow up of 6 to 18 months …”

“…4 Significant reduction in IOP from baseline has also been demonstrated in patients with mild to moderate glaucoma treated with stent insertion alone at follow up of 6 to 18 months. 5 Although each trabecular micro-bypass device has proven to be efficacious, the two devices have not been previously compared in performance and efficacy.…”

Short‐term results of microhook ab interno trabeculotomy, a novel minimally invasive glaucoma surgery in Japanese eyes: initial case series

“…), iStent (Glaukos, Laguna Hills, CA; Malvankar‐Mehta et al. ), gonioscopy‐assisted transluminal trabeculotomy (Grover et al. ; Sato et al.…”

Steroid‐induced glaucoma treated with trabecular ablation in a matched comparison with primary open‐angle glaucoma

“…We observed a greater decrease in IOP from a higher baseline IOP compared with a prior study that uses a trabecular microbypass stent . In that study, the IOP decreased with standalone iStent implantation 22% from a baseline near 24 mmHg on one less medication ( vs . our AIT 47% decrease from a baseline of 32 mmHg on 1.5 less medications).…”